Bonesupport Holding AB (BONEX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bonesupport Holding AB (BONEX) has a cash flow conversion efficiency ratio of 0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.09 Million ≈ $7.65 Million USD) by net assets (Skr835.89 Million ≈ $89.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bonesupport Holding AB (BONEX) market capitalisation for the company's overall valuation and market capitalisation.
Bonesupport Holding AB - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Bonesupport Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bonesupport Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bonesupport Holding AB ranked by their cash flow conversion efficiency. Explore cash flow quality index of Bonesupport Holding AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guodian Nanjing Automation Co Ltd
SHG:600268
|
0.290x |
|
Dongfeng Automobile Co Ltd
SHG:600006
|
0.072x |
|
MCC Meili Paper Industry Co Ltd
SHE:000815
|
0.059x |
|
Appian Corp
NASDAQ:APPN
|
-0.115x |
|
Shanghai Luoman Lighting Technologies Inc.
SHG:605289
|
0.015x |
|
Seojin System Co.Ltd
KQ:178320
|
-0.213x |
|
Domain Holdings Australia Limited
F:3DH
|
0.011x |
|
Mayr-Melnhof Karton AG
VI:MMK
|
0.120x |
Annual Cash Flow Conversion Efficiency for Bonesupport Holding AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Bonesupport Holding AB from 2014 to 2024. View Bonesupport Holding AB share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr727.46 Million ≈ $78.29 Million |
Skr65.76 Million ≈ $7.08 Million |
0.090x | +369.93% |
| 2023-12-31 | Skr545.18 Million ≈ $58.67 Million |
Skr-18.26 Million ≈ $-1.96 Million |
-0.033x | +80.83% |
| 2022-12-31 | Skr268.93 Million ≈ $28.94 Million |
Skr-46.98 Million ≈ $-5.06 Million |
-0.175x | +44.35% |
| 2021-12-31 | Skr265.70 Million ≈ $28.59 Million |
Skr-83.42 Million ≈ $-8.98 Million |
-0.314x | -24.90% |
| 2020-12-31 | Skr398.90 Million ≈ $42.93 Million |
Skr-100.28 Million ≈ $-10.79 Million |
-0.251x | +80.93% |
| 2019-12-31 | Skr124.31 Million ≈ $13.38 Million |
Skr-163.83 Million ≈ $-17.63 Million |
-1.318x | -113.88% |
| 2018-12-31 | Skr278.53 Million ≈ $29.97 Million |
Skr-171.62 Million ≈ $-18.47 Million |
-0.616x | -158.30% |
| 2017-12-31 | Skr450.79 Million ≈ $48.51 Million |
Skr-107.53 Million ≈ $-11.57 Million |
-0.239x | +90.01% |
| 2016-12-31 | Skr34.30 Million ≈ $3.69 Million |
Skr-81.93 Million ≈ $-8.82 Million |
-2.388x | +25.64% |
| 2015-12-31 | Skr20.33 Million ≈ $2.19 Million |
Skr-65.29 Million ≈ $-7.03 Million |
-3.212x | -404.36% |
| 2014-12-31 | Skr-43.52 Million ≈ $-4.68 Million |
Skr-45.92 Million ≈ $-4.94 Million |
1.055x | -- |
About Bonesupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin duri… Read more